The maintenance of stable plasma drug concentrations within a therapeutic window can be critical for drug efficacy. Here, we developed a wearable osmotic microneedle (OMN) patch to support sustained drug dosing for at least 24 hours without the use of electronic components. The OMN patch uses an osmotic pressure driving force to deliver drug solution into the skin through three hollow microneedles with diameters of less than 200 micrometers. The rate of drug release was related to the composition and concentration of the osmogen and drug and to the physical properties of the semipermeable membrane separating the low- and high-solute compartments. The OMN patch released the peptide drug exenatide in rats and mice for 24 hours, whereas subcutaneous injection resulted in a burst release and rapid decline in the plasma drug concentration. OMN release of exenatide improved glycemic control in a diabetic mouse model consistent with a sustained effective plasma concentration of the drug. Continuous release of the small-molecule chemotherapeutic drug cytarabine reduced the progression of acute myeloid leukemia in mice more effectively than subcutaneous injection. Further evaluation of the OMN patch in canines demonstrated continuous dosing of cytarabine up to 225 milligrams for 24 hours, satisfying clinical requirements (150 to 300 milligrams daily). OMN patches were well tolerated in human participants with minimal pain or irritation of the skin and a stated preference over other administration routes. This wearable drug delivery system could provide a platform for stable high-dose drug release with convenience and safety.
Tumor-targeted delivery of oncolytic viruses (OVs) via systemic administration could not only expand virotherapy beyond primary tumors to widespread metastases, but also improve clinical adherence and convenience. We here engineer megakaryocytes encapsulating oncolytic adenovirus type 5 (M-Ad5) to produce oncolytic platelets in vivo by leveraging the thrombopoiesis process. Upon intravenous administration, M-Ad5 travels through the lungs, where it can release OVs-harbored therapeutic platelets into circulation under pulmonary turbulence microenvironments. Under the shelter of platelets, OVs resist inactivation by neutralizing antibodies and actively target widespread noninjectable cancer lesions. Intravenous infusion of M-Ad5 to mice with A549 lung cancer could significantly inhibit tumor growth and prolong survival. In multiple mouse tumor models, M-Ad5 induced a robust antitumor immune response by reprogramming the immunosuppressive tumor microenvironment, and potentiated the response to immune checkpoint inhibitors by recruiting more immune cells. We demonstrated that M-Ad5 in combination with PDL1 inhibitors activated tumor antigen-specific CD8 + T cells and memory T cells, thereby suppressing the growth of CT26 colorectal cancer metastasis, and preventing postsurgical B16F10 cancer recurrence and metastatic spread, as well as providing long-term immune protection against the rechallenged tumors.
Successful treatment of resectable intestinal diseases hinges on advanced intestinal anastomosis techniques and effective postoperative management. However, current postoperative adjuvant therapy remains limited to systemic administration of medications after conventional hand-sewn anastomosis, frequently leading to associated complications and potential recurrence. Here, we introduce a microneedle anastomotic stent (MAS) for postoperative intestinal healing and localized drug delivery in resectable intestinal diseases. This MAS integrates a biodegradable polyglycolic acid stent with a stimulus-responsive polyprodrug microneedle patch. This design provides robust mechanical properties, effective prevention of anastomotic leakage, and on-demand drug release at the anastomotic site. After intestinal resection, the MAS is implanted at the anastomotic site, where the microneedles penetrate the mucosal layer and release the anti-inflammatory drug in response to hyperinflammatory conditions, thereby attenuating local inflammation and facilitating anastomotic healing. In vitro assays verified the minimal cytotoxicity and good biocompatibility of the MAS and its degradation products. The efficacy of the MAS in tissue penetration and stimulus-responsive drug release was demonstrated using ex vivo patient samples. The in vivo therapeutic benefit and mechanism of the MAS were validated in the murine radiation colitis model, and its feasibility and safety were further confirmed in the minipig model of ischemic inflammatory injury. The MAS also exhibited versatility as a delivery platform for diverse therapeutics, suggesting potential applications in complex intestinal diseases. Compared with conventional methods, in preclinical studies, the MAS offered a sutureless approach for intestinal anastomosis and postoperative adjuvant therapy, holding potential for treating various resectable intestinal diseases.